Retrovirology

official impact factor 5.24

This article is part of the supplement: AIDS Vaccine 2009

Open Access Oral presentation

S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania

RN Koehler1*, AM Walsh1, E Saathoff2, JR Currier1, CT Bautista1, N Moqueet1, S Ratto-Kim1, L Maboko3, M Hoelscher2, ML Robb1, NL Michael4, FE McCutchan1, JH Kim4 and GH Kijak1

  • * Corresponding author: RN Koehler

Author Affiliations

1 US Military HIV Research Program/Henry M Jackson Foundation, Rockville, MD, USA

2 Dept. of Infectious Diseases & Tropical Medicine, Univ. of Munich, Munich, Germany

3 Mbeya Medical Research Program, Mbeya, Tanzania

4 US Military HIV Research Program, WRAIR, Rockville, MD, USA

For all author emails, please log on.

Retrovirology 2009, 6(Suppl 3):O2 doi:10.1186/1742-4690-6-S3-O2

Published: 22 October 2009

First paragraph (this article has no abstract)

Genetic variation in class I HLA impacts the strength, breadth, and depth of anti-HIV adaptive cellular immune responses, while also influencing innate immunity via interaction with killer immunoglobulin receptors (KIR) on natural killer (NK) cells. Allele HLA-A*7401 is found almost exclusively in sub-Saharan African populations with little known about the immune responses it restricts. The objective of this exploratory study was to investigate the effects of HLA-A*7401 on disease progression and risk of HIV-1 acquisition in an East African cohort population.